Alza Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mountain View CA United States (1968)
Status: Acquired by Johnson and Johnson (2001)

Organization Overview

First Clinical Trial
1986
NCT00269737
First Marketed Drug
1974
pilocarpine (ocusert)
First NDA Approval
1974
pilocarpine (ocusert)
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ALZA | Alza Corporation, DE, USA

Indications

Approved Indications


 

Amenorrhea

Glaucoma, Angle-Closure

Glaucoma, Open-Angle

Head and Neck Neoplasms

Ocular Hypertension

Sjogren's Syndrome

Uterine Hemorrhage

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Back Pain (Phase 3)

Cancer Pain (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Chronic Pain (Phase 3)

Colorectal Neoplasms (Phase 2)

Disease (Phase 2)

Enuresis (Phase 3)

Erectile Dysfunction (Phase 3)

Hyperkinesis (Phase 3)

Low Back Pain (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Narcolepsy (Phase 2)

Neoplasms (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Hip (Phase 3)

Osteoarthritis, Knee (Phase 3)

Ovarian Neoplasms (Phase 3)

Pain, Postoperative (Phase 4)

Preleukemia (Phase 2)

Premature Ejaculation (Phase 3)

Prostatitis (Phase 2)

Psoriasis (Phase 2)

Syndrome (Phase 2)

Urinary Bladder, Overactive (Phase 3)

Urinary Incontinence (Phase 3)

Urinary Incontinence, Urge (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 24